- Home
- PHAR vs IRMD Comparison
PHAR vs IRMD Comparison
Compare PHAR & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- IRMD
- Stock Information
- Founded
- PHAR 1988
- IRMD 1992
- Country
- PHAR Netherlands
- IRMD United States
- Employees
- PHAR N/A
- IRMD N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- IRMD Medical/Dental Instruments
- Sector
- PHAR Health Care
- IRMD Health Care
- Exchange
- PHAR Nasdaq
- IRMD Nasdaq
- Market Cap
- PHAR 718.1M
- IRMD 756.5M
- IPO Year
- PHAR N/A
- IRMD 2014
- Fundamental
- Price
- PHAR $10.65
- IRMD $61.54
- Analyst Decision
- PHAR Strong Buy
- IRMD Strong Buy
- Analyst Count
- PHAR 3
- IRMD 1
- Target Price
- PHAR $30.00
- IRMD $72.00
- AVG Volume (30 Days)
- PHAR 4.4K
- IRMD 60.3K
- Earning Date
- PHAR 07-31-2025
- IRMD 07-31-2025
- Dividend Yield
- PHAR N/A
- IRMD 1.11%
- EPS Growth
- PHAR N/A
- IRMD 10.72
- EPS
- PHAR N/A
- IRMD 1.55
- Revenue
- PHAR $320,708,000.00
- IRMD $75,154,639.00
- Revenue This Year
- PHAR $13.31
- IRMD $10.62
- Revenue Next Year
- PHAR $7.68
- IRMD $9.69
- P/E Ratio
- PHAR N/A
- IRMD $39.64
- Revenue Growth
- PHAR 24.13
- IRMD 11.04
- 52 Week Low
- PHAR $6.65
- IRMD $42.34
- 52 Week High
- PHAR $12.61
- IRMD $63.29
- Technical
- Relative Strength Index (RSI)
- PHAR 49.05
- IRMD 65.04
- Support Level
- PHAR $10.46
- IRMD $59.50
- Resistance Level
- PHAR $11.49
- IRMD $60.94
- Average True Range (ATR)
- PHAR 0.36
- IRMD 1.58
- MACD
- PHAR -0.12
- IRMD -0.04
- Stochastic Oscillator
- PHAR 31.46
- IRMD 92.45
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.